{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "DKK", "exchange": "IOB", "shortName": "ZEALAND PHARMA A/S ZEALAND PHAR", "longName": "Zealand Pharma A/S", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": 6.7219963, "regularMarketPrice": 257.2, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -20.63, "sharesOutstanding": 58351900, "bookValue": 15.852, "fiftyDayAverage": 226.34703, "fiftyDayAverageChange": 30.852982, "fiftyDayAverageChangePercent": 0.13630831, "twoHundredDayAverage": 190.41917, "twoHundredDayAverageChange": 66.78084, "twoHundredDayAverageChangePercent": 0.35070437, "marketCap": 15352654848, "priceToBook": 16.225082, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1300176000000, "priceHint": 2, "regularMarketChange": 16.200012, "regularMarketTime": 1683913508, "regularMarketDayHigh": 259.6, "regularMarketDayRange": "235.4 - 259.6", "regularMarketDayLow": 235.4, "regularMarketVolume": 81586, "regularMarketPreviousClose": 241.0, "bid": 249.8, "ask": 263.6, "bidSize": 0, "askSize": 0, "fullExchangeName": "IOB", "financialCurrency": "DKK", "regularMarketOpen": 238.0, "averageDailyVolume3Month": 38609, "averageDailyVolume10Day": 38700, "fiftyTwoWeekLowChange": 187.15001, "fiftyTwoWeekLowChangePercent": 2.671663, "fiftyTwoWeekRange": "70.05 - 259.6", "fiftyTwoWeekHighChange": -2.399994, "fiftyTwoWeekHighChangePercent": -0.009244968, "fiftyTwoWeekLow": 70.05, "fiftyTwoWeekHigh": 259.6, "trailingAnnualDividendRate": 0.0, "symbol": "0NZU.IL"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Sydmarken 11", "address2": "SOeborg", "city": "Copenhagen", "zip": "2860", "country": "Denmark", "phone": "45 88 77 36 00", "fax": "45 88 77 38 98", "website": "https://www.zealandpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 196, "companyOfficers": [{"maxAge": 1, "name": "Mr. Adam Sinding Steensberg M.D.", "age": 48, "title": "Pres & CEO", "yearBorn": 1974, "fiscalYear": 2021, "totalPay": {"raw": 5146000, "fmt": "5.15M", "longFmt": "5,146,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Henriette  Wennicke", "age": 39, "title": "EVP & CFO", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ivan Mourits Moller", "age": 50, "title": "Exec. VP & COO", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mads  Kronborg", "title": "Head of Investor Relations & Communication", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ravinder  Chahil", "age": 54, "title": "Sr. VP & Gen. Counsel", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Christina Sonnenborg Bredal", "age": 37, "title": "Sr. VP and Global Head of People & Organization", "yearBorn": 1985, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jens Damsgaard Mikkelsen M.D.", "title": "Head of Molecular Pharmacology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Danilo  Verge", "title": "Head of Global Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David M. Kendall M.D.", "age": 61, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Lykke  Romer", "title": "VP & Head of Fin. and Accounting", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 4, "boardRisk": 1, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}